m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04049)
Name
ASTX295
Status
Phase 1/2
TTD Drug ID
DE7N6F
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ubiquitin-protein ligase E3 Mdm2 (MDM2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ASTX295. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ASTX295 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ASTX295. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ASTX295 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [1], [2]
References
Ref 1 The m(6)A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022 Jan 4;13(3):1019-1030. doi: 10.7150/jca.60381. eCollection 2022.
Ref 2 Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41. doi: 10.1021/jm500627s. Epub 2014 Jul 9.